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Background: Current cancer mortality figures are important for disease management and resource allocation. We
estimated mortality counts and rates for 2020 in the European Union (EU) and for its six most populous countries.
Materials and methods: We obtained cancer death certification and population data from the World Health
Organization and Eurostat databases for 1970e2015. We estimated projections to 2020 for 10 major cancer sites
plus all neoplasms and calculated the number of avoided deaths over 1989e2020.
Results: Total cancer mortality rates in the EU are predicted to decline reaching 130.1/100 000 men (5.4% since 2015)
and 82.2 in women (4.1%) in 2020. The predicted number of deaths will increase by 4.7% reaching 1 428 800 in 2020.
In women, the upward lung cancer trend is predicted to continue with a rate in 2020 of 15.1/100 000 (higher than that
for breast cancer, 13.5) while in men we predicted further falls. Pancreatic cancer rates are also increasing in women
(þ1.2%) but decreasing in men (1.9%). In the EU, the prostate cancer predicted rate is 10.0/100 000, declining by
7.1% since 2015; decreases for this neoplasm are w8% at age 45e64, 14% at 65e74 and 75e84, and 6% at 85 and
over. Poland is the only country with an increasing prostate cancer trend (þ18%). Mortality rates for other cancers
are predicted to decline further. Over 1989e2020, we estimated over 5 million avoided total cancer deaths and
over 400 000 for prostate cancer.
Conclusion: Cancer mortality predictions for 2020 in the EU are favourable with a greater decline in men. The number
of deaths continue to rise due to population ageing. Due to the persistent amount of predicted lung (and other
tobacco-related) cancer deaths, tobacco control remains a public health priority, especially for women. Favourable
trends for prostate cancer are largely attributable to continuing therapeutic improvements along with early diagnosis.
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Since 2011 we have been projecting cancer mortality trends
for the current year in major countries from the European
Union (EU) and in the EU as a whole.1e3 We predicted
steady declines in mortality rates by about 1.5% in men and
0.8% in women over recent years. These are similar to the
US trends in males but proportionally smaller compared
with those reported for women in the USA (1.8%).4
Nevertheless, due to population growth and ageing, the
number of cancer deaths was still increasing.5,6 Persistent
disparities across countries in cancer rates were observed*Correspondence to: Prof. C. La Vecchia, Department of Clinical Sciences and
Community Health, Universitá degli Studi di Milano, Via Vanzetti 5, 20122
Milan, Italy. Tel: þ39-02-503-20-863; Fax: þ39-02-503-20-866
E-mail: carlo.lavecchia@unimi.it (C. La Vecchia).
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650 https://doi.org/10.1016/j.annonc.2020.02.009with generally higher rates and less favourable trends for
Central and Eastern Europe.
This work provides an up-to-date picture of mortality
patterns in the form of mortality counts and age-
standardised rates in the EU for the year 2020, with a
specific focus on prostate cancer.
MATERIALS AND METHODS
We extracted death certification data for all cancers com-
bined and 10 major cancer sites from the World Health
Organization (WHO) database.7 We recoded cancer deaths
according to the 10th International Classification of Disease
(ICD) Revision8: total cancers (ICD codes C00eD48), stom-
ach (C16), colorectum (C17eC21, C26), pancreas (C25), lung
(C33eC34), breast (C50), uterus (cervix and corpus) (C53e
C55), ovary (C56), prostate (C61), bladder (C67), and leu-
kemias (C91eC95). We retrieved figures from 1970 to 2015
for the EU (defined as the 28 member states excluding
Cyprus due to excessive missing data) and up to the mostVolume 31 - Issue 5 - 2020
G. Carioli et al. Annals of Oncologyrecent available year for its six most populous countries:
2015 for France and Italy and 2016 for Germany, Poland,
Spain, and the UK. We obtained corresponding resident
population data, based on official censuses, from the same
WHO database7 and when data were missing from
Eurostat.9
From the matrices of certified deaths and resident
population we computed country- and sex-specific death
rates for each 5-year age group (from 0e4 to 85þ years),
calendar year, and quinquennium. We standardised
mortality rates by age using the world standard population
for all ages and, for prostate cancer, also for selected age
groups.10 We also fit joinpoint regression models11
including up to four joinpoints to age-standardised rates.
To predict mortality figures we applied a Poisson join-
point regression model11 to the number of deaths (log
scale) in each 5-year age group. This identified significant
changes in trends testing up to five joinpoints. To estimate
the age-specific number of deaths for 2020 and the cor-
responding 95% prediction intervals (PIs) we fitted a linear
regression model to the mortality data for each age group
over the most recent trend segment with at least 5 data
points identified by the joinpoint model. Using the pre-
dicted age-specific- death counts from our model and the
predicted populations (obtained from Eurostat9) we
computed predicted age-specific and age-standardised
death rates and their 95% PIs.
We estimated numbers of avoided total cancer deaths
over the years 1989e2020 by comparing observed and
expected deaths on the basis of the 1988 age-specific peak
rates. We also estimated the number of avoided prostate
cancer deaths since 1996, i.e. the peak EU rate for prostate
cancer.Table 1. Number of predicted deaths and mortality rate for the year 2020, compa
percentage differences between 2015 and 2020
Observed number of
deaths 2015
Predicted num
deaths 2020 (
Men
Stomach 34 666 33 700 (32 9
Colorectum 93 241 98 500 (96 7
Pancreas 42 462 45 900 (45 3
Lung 183 943 182 600 (179
Prostate 74 998 78 800 (77 6
Bladder 31 938 32 800 (32 0
Leukemias 23 713 25 100 (24 4
All cancers (malignant and benign) 760 111 798 700 (791
Women
Stomach 22 162 20 300 (19 6
Colorectum 77 122 76 100 (74 9
Pancreas 42 201 46 200 (45 4
Lung 88 502 99 800 (98 6
Breast 93 903 95 900 (94 6
Uterus (cervix and corpus) 29 691 31 300 (30 6
Ovary 30 213 29 000 (28 3
Bladder 10 900 11 400 (11 1
Leukemias 19 137 19 800 (19 3
All cancers (malignant and benign) 603 957 630 100 (625
ASR, age-standardised mortality rates using the world standard population.
Volume 31 - Issue 5 - 2020RESULTS
Table 1 gives the EU predicted number of deaths and age-
standardised mortality rates for 2020 with corresponding
95% PIs as well as the observed figures for 2015 and the
percentage differences between 2015 and 2020 in men and
women. Overall cancer mortality rate in the EU is predicted
to decline in men from 137.5/100 000 in 2015 to 130.1 in
2020 (5.4%) and in women from 85.7 to 82.2 (4.1%). The
overall number of cancer deaths is however predicted
to increase by 4.7% from 1 364 068 cancer deaths in 2015
(760 111 men, 603 957 women) to 1 428 800 in 2020
(798 700 men, 630 100 women).
Figure 1 displays EU age-standardised mortality rates
observed for 2015 and predicted for 2020 with corre-
sponding 95% PIs for total cancers and the 10 major cancer
sites in men and women. The highest EU predicted rates in
both sexes are for lung cancerd31.6/100 000 men and 15.1
in women. Lung cancer rates decline by 9.2% between 2015
and 2020 in men while they increase by 6.0% in women.
The total deaths from lung cancer estimated for 2020 (182
600 men, 99 800 women) still are about 20% of all cancer
deaths. In women, the predicted lung cancer mortality
rate is now appreciably higher than that of breast cancer,
13.5/100 000 (7.3% since 2015) and the number of deaths
from lung cancer is also greater than that from breast
cancer (99 800 and 95 900, respectively). The colorectal
cancer rate for 2020 is 15.4/100 000 men and 8.6 in women
with a smaller fall in men since 2015 (4.2% in men
versus 8.3% in women). Prostate cancer is the third pre-
dicted cause of cancer deaths in EU men with 78 800 deaths
in 2020 and a rate of 10.0/100 000 (7.1% since 2015).
Pancreatic cancer predicted rates are 7.8 in men and 5.6 in
women with inconsistent trends over time. Stomach cancerrison figures for 2015, for the EU, with 95% prediction intervals (PIs) and the
ber of
95% PI)
Observed
ASR 2015
Predicted ASR
2020 (95% PI)
% difference
2020/2015
71e34 485) 6.28 5.53 (5.39e5.67) 11.9
50e100 316) 16.06 15.38 (15.08e15.68) 4.2
50e46 534) 7.91 7.76 (7.65e7.87) 1.9
799e185 440) 34.83 31.62 (31.02e32.21) 9.2
46e80 026) 10.71 9.95 (9.78e10.11) 7.1
36e33 618) 4.99 4.52 (4.38e4.65) 9.4
89e25 707) 4.39 3.87 (3.73e4.02) 11.8
039e806 298) 137.53 130.09 (128.63e131.55) 5.4
98e20 900) 2.91 2.51 (2.42e2.6) 13.7
44e77 260) 9.40 8.62 (8.48e8.75) 8.3
94e46 975) 5.53 5.60 (5.49e5.7) 1.2
58e100 983) 14.28 15.13 (14.95e15.32) 6.0
37e97 187) 14.54 13.48 (13.31e13.66) 7.3
56e31 974) 4.84 4.78 (4.67e4.89) 1.2
30e29 696) 4.78 4.23 (4.11e4.36) 11.5
14e11 656) 1.17 1.15 (1.12e1.18) 1.9
90e20 184) 2.63 2.27 (2.17e2.37) 13.7
252e634 898) 85.68 82.16 (81.59e82.73) 4.1
https://doi.org/10.1016/j.annonc.2020.02.009 651
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Figure 1. Bar-plots of age-standardised (world population) death rates per 100 000 persons for the year 2015 (left columns) and predicted rates for 2020 (right
columns) with 95% prediction intervals for total cancers and 10 major cancer sites in EU men and women.
Annals of Oncology G. Carioli et al.rates continue to decline steadily (around 12% in men
and 14% in women) reaching values of 5.5/100 000 in
men and of 2.5 in women for 2020. Uterine and ovarian
cancer rates for 2020 are 4.8/100 000 (1.2% fall since
2015) and 4.2 (11.5%), respectively. Leukemia rates
decline over 10% between 2015 and 2020 in both sexes.
Bladder cancer rates decrease by 9.4% (4.5/100 000) in men
but only by 1.9% in women (1.2/100 000).
Figure 2 shows EU mortality trends for all cancers and the
10 major cancer sites between 1970 and 2020. In EU men,
all cancer mortality has been declining since the late 1980s
mainly driven by favourable mortality rates from lung and
stomach cancers. Male trends for colorectal, prostate, and
bladder cancers increase up to the early 1990s and then
decrease. In EU women, all cancer mortality rates fell over
the whole period studied. Steady declines were observed in
female mortality trends for breast cancer since the 1990s
and for colorectal, stomach, and uterine cancers over the
whole period. Ovarian cancer rose until 1990 and then
declined thereafter. The lung cancer trend in women has
been increasing over the whole period with rates overtaking
those of breast cancer in the mid-2010s. In both sexes,
pancreatic cancer trends showed steady rises over the
studied period; in men, however, in the predicted period
there is a levelling of rates. Mortality from leukemias
declined in both sexes. Additional country-specific data and
analyses are available in the supplementary Tables S1eS9
and Figures S1 and S2, available at Annals of Oncology
online. Trends and predictions are less favourable in Poland
than in Western Europe and total mortality remains
consequently higher in both sexes.
Figure 3 displays mortality trends in quinquennial rates
for prostate cancer in the EU as a whole and in its six most652 https://doi.org/10.1016/j.annonc.2020.02.009populous countries between 1970 and 2020. Prostate can-
cer rates rose up to the late 1980s in France and Italy to
then decline up to 2020. In the UK, Germany, as well as in
the EU as a whole rates were higher and decreases started
about 5 years later. Spain had an increasing trend up to the
late 1990s, falling thereafter. Poland showed the most
unfavourable trend; starting from the lowest rate in the
1970e1974 quinquennium, the trend increased up to the
early 2000s, had a tendency to stabilise to then rise again
up to 2020. Thus, Polish cancer rates are now the highest
predicted.
Table 2 shows all age mortality rates from prostate can-
cer observed in 2005e2009 and 2010e2014 and those
predicted for 2020 with corresponding 95% PIs in the six
studied countries and for the EU also for the 45e64, 65e74,
75e84, and 85þ age groups. Percentage differences be-
tween rates in 2010e2014 and 2020 are included as well.
The lowest prostate cancer rates in 2020 are in Italy (5.8/
100 000), Spain (7.2), and France (7.3), which also have the
greatest declines between 2010e2014 and 2020 with per
cent changes over 20%. Germany and the UK have pre-
dicted rates of about 11/100 000 men with falls of 7.4% and
9.0% since 2010e2014, respectively. The Polish predicted
trend rises by 17.9%, reaching a rate of 14.7. Considering
age-group-specific trends in the EU, rates for men aged
45e64 decline by 8.4% and those for men aged 65e74
and 75e84 decline by about 14%. The fall was 5.8% at age
85 and over.
Figure 4 displays joinpoint analysis results for the EU
annual prostate cancer mortality rates in all ages and in
selected age groups between 1970 and 2020. In the EU,
prostate cancer mortality trends for the truncated ages
45e64 and 75e84 started to decline around 1990Volume 31 - Issue 5 - 2020
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Figure 3. Age-standardised (world population) cancer mortality rate trends for all ages in quinquenniums from 1970e1974 to 2010e2014 and predicted rates for
2020 with 95% prediction intervals for prostate cancer in studied countries and in the EU as a whole.
Annals of Oncology G. Carioli et al.(supplementary Table S9, available at Annals of Oncology
online); men aged 65e74 showed an earlier fall (since the
late 1980s) and a flatter pattern over the period.
Figure 5 shows EU total cancer averted deaths between
the highest rate in 1988 and 2020 in men and women. Over
the years between 1989 and 2020, for the EU, we estimated
a total of 5 685 000 avoided cancer deaths (3 796 000 in
men and 1 889 000 in women). In 2020, we predicted 406
000 averted deaths (282 000 in men and 124 000 in
women). For prostate cancer (Figure 6) we estimated 462Table 2. Age-standardised prostate cancer mortality rates for all ages in selected
75e84, and 85D years in the 2005e2009 and 2010e2014 quinquenniums and pr
ASR 2005e2009 ASR 2010e
France 12.11 9.93
Germany 11.96 11.46
Italy 8.98 7.66
Poland 13.02 12.44
Spain 10.05 9.24
UK 14.05 13.17
EU
All ages 12.21 11.17
Truncated 45e64 years 8.02 7.45
Truncated 65e74 years 72.91 66.41
Truncated 75e84 years 248.11 219.81
Truncated 85þ years 658.55 623.13
ASR, age-standardised mortality rates using the world standard population.
654 https://doi.org/10.1016/j.annonc.2020.02.009000 avoided cancer deaths over the 32-year period and 40
000 in 2020 alone. Thus, over 12% of cancer deaths were
avoided in men over the last three decades and over 14%
over recent years due to prostate cancer alone.DISCUSSION
Total cancer mortality predictions for 2020 in the EU are
favourable with a 5% decline in rates in men and 4% in
women since 2015. Nevertheless, the number of deathsEuropean countries and for the EU as a whole for all ages, 45e64, 65e74,
edicted for 2020 with percentage differences between 2010e2014 and 2020
2014 Predicted ASR
2020 (95% PI)
% difference 2020
2010e2014
7.29 (6.84e7.74) 26.6
10.61 (10.11e11.12) 7.4
5.79 (5.57e6.01) 24.4
14.67 (13.79e15.55) 17.9
7.24 (6.87e7.62) 21.6
11.99 (11.52e12.46) 9.0
9.95 (9.78e10.11) 11.0
6.82 (6.38e7.27) 8.4
57.17 (55.05e59.29) 13.9
189.95 (184.88e195.02) 13.6
587.05 (575.68e598.42) 5.8
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Figure 4. Annual prostate cancer age-standardised (world population) death rates in the EU per 100 000 for all ages, 45e64, 65e74, 75e84, and 85D age-groups
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groups.
G. Carioli et al. Annals of Oncologycontinues to rise due to population ageing. There is no
consistent decline in pancreatic cancer mortality, which
remains therefore a major public health issue. Lung can-
cer rates in women continue to increase, reaching an over
15/100 000 rate in 2020. As in previous reports, trends
are less favourable and cancer rates continue to be
appreciably higher in Poland as compared with major
Western European countries, thus indicating a persistent
gap in cancer mortality between Central-Eastern and
Western Europe.12
Tobacco remains the main cause of cancer mortality in
Europe and the more marked decline in overall cancer
mortality trends in men compared to women largely re-
flects the differences in past smoking patterns between the
two sexes.13 Reduced occupational exposure to asbestos
and other lung carcinogens, which has likely affected more
males than females, may also partly explain the more
favourable trend in men. Lung cancer in both sexes com-
bined still accounts for around 20% of total predicted can-
cer deaths, highlighting the persisting importance and
priority of tobacco prevention programmes.14,15
The pancreas is the only cancer site not showing
consistent declines. Nevertheless, predictions for men inVolume 31 - Issue 5 - 20202020 are levelling in the EU overall though with appreciable
differences on a country level. The different patterns of
tobacco smoking in subsequent generations of men and
women cannot entirely explain the less marked decrease
compared with other tobacco-related cancers. Excessive
weight and diabetes play a role in its etiology and have
been increasing in most European countries over the last
few decades.16 Still, their role in such unfavourable patterns
for both sexes can hardly be quantified and pancreatic
cancer mortality trends and predictions remain difficult to
explain.17
Bladder cancer predicted rates in EU men are around
fourfold higher than those in women. Besides the important
effect of tobacco, occupational carcinogens such as aro-
matic amines may also explain this gap. The reduced
occupational exposure to aromatic amines over the last
several decades may account for the much more favourable
trends and predictions in men than women.18
The persisting favourable trends in stomach cancer
mortality in both sexes across Europe including countries
with lower rates are likely due to the reduction in Heli-
cobacter pylori infection, decreased smoking levels in men,
healthier diet, and better food conservation.19https://doi.org/10.1016/j.annonc.2020.02.009 655
1970 1980 1990 2000 2010 2020
Calendar year
To
ta
l c
an
ce
r d
ea
th
s
0
50
0 0
00
1  0
00
 
00
0
Avoided deaths
Deaths
Deaths estimated from 1988 age-specific rates
Men
1970 1980 1990 2000 2010 2020
Calendar year
To
ta
l c
an
ce
r d
ea
th
s
0
50
0 0
00
1 0
00
 
00
0
Avoided deaths
Deaths
Deaths estimated from 1988 age-specific rates
Women
Figure 5. Total avoided cancer deaths for EU men and women between the top rate in 1988 and 2020; observed numbers of cancer deaths from 1970 to 2015 and
predicted cancer deaths from 2016 to 2020; estimated numbers of total cancer deaths by applying 1988 age-specific peak mortality rate.
During the 32-year period 5 685 000 cancer deaths have been avoided (3 796 000 in men and 1 889 000 in women). In 2020 alone the number of cancer deaths
predicted to be avoided are 282 000 in men and 124 000 in women for a total of 406 000.
Annals of Oncology G. Carioli et al.The decreasing trends in colorectal cancer are a conse-
quence of progresses in screening, early diagnosis, and
treatment.20 The reason for the persisting more favourable
trend in women remains largely unexplained.
Major falls over the last three decades were observed in
breast cancer as well, reflecting advancements in terms of
early diagnosis and treatment.3,21 A favourable role of the
declining use of hormone replacement therapy after 2003
on breast cancer rates is also possible.22
Death certification data from the WHO do not permit
differentiation between cervical and endometrial cancer;
declines in rates from uterine cancer are mainly due to cer-
vical cancer screening and early diagnosis.23 Improvements in
disease management likely influence the falling rates of
uterine cancer, which are difficult to quantify. The levelling of
rates observed in the most recent period probably reflects
trends in endometrial cancer mortality.
The spread of oral contraceptive use across Europe largely
influenced the declining trends in ovarian cancer, in the UK
earlier and subsequently in other countries. The declining use
of hormone replacement therapy and the role of improved
diagnosis and treatment, though difficult to quantify, has also
positively influenced trends for this cancer site.24
The adoption of modern treatment of acute and chronic
leukemias in adults also (i.e. new immunotherapeutics,656 https://doi.org/10.1016/j.annonc.2020.02.009antibodies, tyrosine kinase inhibitors) is the most likely
underlying reason for the continuous falls in overall mor-
tality from leukemias.25
Although prostate cancer is a frequent neoplasm, only
limited modifiable risk factors are recognised, thus limiting
the scope of primary prevention. Obesity, and lack of
physical activity are determinants of prostate cancer, but
the recent patterns in the prevalence of these risk factors in
Europe16 cannot account for the favourable trends. Glob-
ally, the highest mortality rates are registered in North and
West Africa and in the Caribbean (age-standardised rates of
23 to 27/100 000 men) due to African ancestry and genetic
susceptibility. The lowest rates are in Asian countries (3 to
8/100 000 men). Most European countries ranked in the
middle with values from 8 to 14/100 000.26 Within Europe,
large (over twofold) and apparently persisting differences in
prostate cancer mortality between Italy and Poland and the
UK are observed and remain partly or largely unexplained.
The smaller and later declines in mortality trends that are
observed in some Central and Eastern countries27e29 are
probably partly due to a delayed and limited access to
modern effective treatments26,30 and Poland is the only
major European country not showing favourable trends and
predictions in prostate cancer rates. Mortality rates have
been declining since the 1990s in Western and NorthernVolume 31 - Issue 5 - 2020
1970 1980 1990 2000 2010 2020
Calendar year
To
ta
l c
an
ce
r d
ea
th
s
0
60
 
00
0
12
0 0
00
Avoided deaths
Deaths
Deaths estimated from 1996 age-specific rates
Prostate cancer
Figure 6. Total avoided prostate cancer deaths for the EU between the top rate in 1988 and 2020; observed numbers of cancer deaths from 1970 to 2015 and
predicted cancer deaths from 2016 to 2020; estimated numbers of total cancer deaths by applying 1988 age-specific peak mortality rate.
During the 32-year period a total of 462 000 cancer deaths have been avoided. In 2020 alone 40 000 are predicted to be avoided.
G. Carioli et al. Annals of Oncologycountries; thus the geographical variability in rates across
those European areas has been reducing somewhat.26,27
Still, the difference between the rates in Italy (5.8) and
those in the UK (12.0) or Poland (14.7) can only be partly
related to our knowledge of the disease.31
These favourable trends mainly reflect improvements in
prostate cancer therapy, including the technological advances
observed for surgery and radiotherapy.32 The key therapy for
metastatic prostate cancer remains androgen deprivation
therapy (ADT).33 Over the last decade, abiraterone acetate
and enzalutamide have been proved to ameliorate clinical
outcomes in cancer unresponsive to previous ADT. These
drugs along with earlier hormonal and chemotherapy
administration improved survival up to 5 years,32,34 thus
avoiding prostate cancer deaths in a population of elderly
patients.
Evaluating the impact of earlier diagnosis, i.e. the changed
frequency of prostate-specific antigen (PSA) measurement
over the years on prostate cancer mortalitydbesides its
major role on disease incidencedis difficult.35 PSA has been
generally recommended at age 50e69 or 75 but its impact on
mortality may well be reflected at older ages too. The ana-
lysed data indicate a decline between age 65 and 84 but a
smaller one below age 64. This may, however, be due to
greater aggressiveness of prostate cancer at younger ages.
The falls in the over 85-year-olds are likely underestimated
due to population ageing, since no further age adjustment isVolume 31 - Issue 5 - 2020possible for this age group. Prostate cancer is common in
elderly and older elderly men, where validity of death certi-
fication is lower. Most likely, improved certification validity
would have increased prostate cancer rates over recent
years. Thus, the predicted fall in prostate cancer rates may be
somewhat underestimated, though quantification is not
possible.
Like any prediction, our estimates should be consid-
ered with caution. We only considered major cancers
and the largest European countries, however, thus
limiting the scope for random variation. Recent changes
in trends and major cohort effects would be difficult to
detect with the models employed; our previous pre-
dictions proved to be reliable and valid. In fact,
comparing observed cancer deaths for 2015dnow
available in the WHO databasedwith our previous pre-
dictions28 showed that the errors in our predictions were
about 2% or less for all neoplasms considered.FUNDING
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